UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000030624
Receipt number R000034968
Scientific Title Comparison of Liraglutide vs. Dulaglutide in type 2 diabetic outpatients using Flash Glucose monitoring (FGM)
Date of disclosure of the study information 2017/12/28
Last modified on 2020/01/06 12:52:16

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparison of Liraglutide vs. Dulaglutide
in type 2 diabetic outpatients
using Flash Glucose monitoring (FGM)

Acronym

Comparison of Liraglutide vs. Dulaglutide
in type 2 diabetic outpatients
using Flash Glucose monitoring (FGM)

Scientific Title

Comparison of Liraglutide vs. Dulaglutide
in type 2 diabetic outpatients
using Flash Glucose monitoring (FGM)

Scientific Title:Acronym

Comparison of Liraglutide vs. Dulaglutide
in type 2 diabetic outpatients
using Flash Glucose monitoring (FGM)

Region

Japan


Condition

Condition

Type 2 diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare the glucose-lowering effect and glycemic variability of liraglutide with these of dulaglutide using Flash Glucose monitoring (FGM).

Basic objectives2

Bio-equivalence

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Glycemic control is estimated as the mean blood glucose (MBG), the area under the glucose curve above 10.0mmol/L (area under the curve [AUC]>10), and the percentage of time above 10.0mmol/L (t>10).The AUC is calculated using the trapezoidal method.
Intraday glycemic variability is assessed as the standard deviation (SD) and the mean amplitude of glycemic excursions (MAGE).
Hypoglycemia, which is defined as a sensor value of <3.9mmol/L, was also calculated as a total time at <3.9mmol/L. Severe hypoglycemia is defined as a sensor value of <2.8mmol/L.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

The CGM examination is carried out at least 14 days after administering liraglutide. Canagliflozin is changed to dulaglutide when the first CGM examination end.

Interventions/Control_2

The CGM examination is carried out at least 28 days after administering dulaglutide. dulaglutide is changed to liraglutide when the first CGM examination end.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients using Glucagon-Like Peptide 1 Receptor Agonist or the patients who judged a physician to need use of the Glucagon-Like Peptide 1 Receptor Agonist newly.

Key exclusion criteria

Patients with diabetic nephropathy more than stage 4 or with abnormal aspartate aminotransferase/alanine aminotransferase elevation (3 X the upper limit of normal) were excluded from this study.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yamada Satoru

Organization

Kitasato University Kitasato Institute Hospital

Division name

Diabetes Center

Zip code


Address

5-9-1 Shirokane, Minato-ku, Tokyo, Japan

TEL

03-3444-6161

Email

Yamada-s@insti.kitasato-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Inoue Gaku

Organization

Kitasato University School of Pharmacy

Division name

Center for Clinical Pharmacy and Clinical Sciences

Zip code


Address

5-9-1 Shirokane, Minato-ku, Tokyo, Japan

TEL

03-5791-6359

Homepage URL


Email

inoueg@pharm.kitasato-u.ac.jp


Sponsor or person

Institute

Kitasato University School of Pharmacy

Institute

Department

Personal name



Funding Source

Organization

Kitasato University School of Pharmacy

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 12 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2017 Year 12 Month 05 Day

Date of IRB

2017 Year 11 Month 10 Day

Anticipated trial start date

2017 Year 12 Month 18 Day

Last follow-up date

2021 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 12 Month 28 Day

Last modified on

2020 Year 01 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034968


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name